V. V. Bardin, N. Y. Adonin, H.-J. Frohn
ARTICLE
several hours and distilled off. The purified solvents were stored over
molecular sieves (3 Å) before use. [Bu4N][BF4] (Fluka), [Bu4N]Br [q (1:1:1:1), J(F, B) = 42 Hz, 3F, BF3] ppm.
(Fluka), and ICl (Fluka) were used as supplied. Chlorine (n mmol) was
–55.0 (m, 3F, CF3), –69.5 (m, 1F, F2trans), –78.2 (m, 1F, F2cis), –138.0
1
Preparation of [Bu4N][trans-C4F9CF=CFBF3]: The salt (485 mg,
82%) was obtained from [Bu4N]Br (322 mg, 1.0 mmol) and K[trans-
prepared by addition of 37% hydrochloric acid (0.8n mL) to KMnO4
(0.8n mmol, 126n mg)[23] in a slow stream of argon. Crude chlorine in
argon was passed through calcinated CaO in a column (D = 0.5 cm,
L = 3 cm) to remove HCl and moisture. Bromine was washed with
concentrated H2SO4 and distilled over P4O10. Bromine trifluoride was
prepared by bubbling of fluorine (25% v/v in nitrogen) into dry bro-
mine at 8–20 °C. The organyltrifluoroborate salts [Bu4N][cis-
C4F9CF=CFBF3] (388 mg, 1.0 mmol) in MeCN (11 mL) as described
1
above. 11B NMR (CH2Cl2): δ = –0.4 [qd, J(B, F) = 38, 2J(B, F1) =
27 Hz, BF3]. 19F NMR (CH2Cl2): δ = –81.3 (3F, F6), –116.5 (2F, F3),
–124.7, –126.4 (4F, F4,5), –143.9 [q (1:1:1:1), 1J(F, B) = 42 Hz, 3F,
BF3], –153.3 (1F, F1), –177.6 (1F, F2) ppm.
C2F5CF=CFBF3],[4]
K[trans-C4H9CF=CFBF3],
K[CF2=CFBF3],
K[trans-C4F9CF=CFBF3],
K[cis-
Preparation of [Bu4N][CF3CϵCBF3]: The salt (404 mg, 88%) was
K[trans-C6H5CF=CFBF3],
prepared
from
[Bu4N][BF4]
(374 mg,
1.13 mmol)
and
C2F5CF=CFBF3],[24] K[CF2=C(CF3)BF3],[14] K[CF3CϵCBF3],[25]
K[C4H9CH=CHBF3], K[C4H9BF3],[11] and K[C6F13BF3][4] were syn-
thesized using published procedures. Solubilities of selected organyl-
fluoroborate salts in different solvents are given in Table S1 (Support-
ing Information).
K[CF3CϵCBF3] (235 mg, 1.17 mmol) in MeCN (3.5 mL) as described
above. 11B NMR (PFB): δ = –2.7 [q, 1J(B, F) = 31 Hz, BF3]. 11B
NMR (CH2Cl2): δ = –3.3 [q, 1J(B, F) = 32 Hz, BF3]. 19F NMR (PFB):
1
δ = –47.4 (s, 3F, F3), –132.8 [q (1:1:1:1), J(F, B) = 31 Hz, 3F, BF3].
19F NMR (CH2Cl2): δ = –49.0 (s, 3F, F3), –136.0 [q (1:1:1:1), 1J(F,
B) = 32 Hz, 3F, BF3].
The synthesis of K[C4H9CϵCBF3] was performed according to ref.[26]
.
K[C4H9CϵCBF3]. 1H NMR (CD3CN): δ = 2.12 [t, 3J(H3, H4) = 7 Hz,
2 H, H3], 1.42 (m, 2CH2), 0.91 [t, 3J(H6, H5) = 7 Hz, 3 H, H6]. 19F
Preparation
of
[Bu4N][trans-C4H9CF=CFBF3]:
Salt
K[C4H9CF=CFBF3] (392 mg, 1.74 mmol) was suspended in MeCN
(5 mL) and [Bu4N]Br (561 mg, 1.74 mmol) was added in one portion.
The suspension was stirred for 1 h. The mother liquor was separated
by sequential centrifugation and decantation and evaporated under re-
duced pressure. The colorless viscous oil was pumped in a vacuum-
desiccator with Sicapent® and gave a solid product (707 mg, 95%).
1H NMR (CDCl3): δ = 2.24 [dtt, 3J(H3, F2) = 24, 4J(H3, H5) = 7,
4J(H3, F1) = 7 Hz, 2 H, H3], 1.35 (m, 2CH2), 0.92 [t, 3J(H6, H5) =
7 Hz, 3 H, H6] [trans-C4H9CF = CFBF3]–; 3.14 (m, 4CH2), 1.54 (m,
1
NMR (CD3CN): δ = –133.6 [q (1:1:1:1), J(F, B) = 38 Hz, 3F, BF3].
1
11B NMR (CD3CN): δ = –1.9 [q, J(B, F) = 38 Hz, BF3]. 19F NMR
([D6]DMSO): δ = –131.1 [broadened q (1:1:1:1), 3F, BF3]. 13C{19F}
NMR ([D6]DMSO): δ = 92.4 (br. m, C-1), 90.3 (m, C-2), 31.8 [t,
1
1J(C-4, H4) = 125 Hz, C-4], 22.2 [t, J(C-5, H5) = 124 Hz, C-5], 19.3
1
[t, J(C-3, H3) = 128 Hz, C-3], 14.2 [q, 1J(C-6, H6) = 125 Hz, C-6].
NMR spectroscopic data in [D6]acetone (cf.[26,27]) are given in
Table S2 (Supporting Information).
4CH2), 1.35 (m, 4CH2), 0.92 [t, 3J(H4, H3)
= 7 Hz, 4CH3]
Manipulations with fluorine and BrF3 were performed in FEP (block
copolymer of tetrafluoroethylene and hexafluoropropylene) or PFA
(block copolymer of tetrafluoroethylene and perfluoroalkoxytrifluoro-
ethylene) equipment in an atmosphere of dry argon. The NMR spectra
of BrF3 and BrF3–Br2 solutions were measured in FEP inliners (Di =
3.50Ϯ0.05 mm, Do = 4.10Ϯ0.05 mm).
[(C4H9)4N]+. 11B NMR (CDCl3): δ = 0.7 (br. s, Δν1/2 = 149 Hz, BF3).
3
3
19F NMR (CDCl3): δ = –158.6 [dtq J(F2, F1) = 119, J(F2, H3) = 24,
4J(F2, BF) = 10 Hz, 1F, F2], –172.5 [d 3J(F1, F2) = 119 Hz, 1F, F1],
–143.6 [broadened q (1:1:1:1), 3F, BF3].
Preparation of [Bu4N][C4H9CH=CHBF3]: The salt (664 mg, 90%)
was obtained as a colorless viscous oil from [Bu4N]Br (603 mg,
1.87 mmol) and K[C4H9CH=CHBF3] (cis/trans = 69:31) (355 mg,
1.87 mmol) in MeCN (15 mL) as described above. 1H NMR (CDCl3):
Preparation of Tetrabutylammonium
Organyltrifluoroborates
3
3
δ = 5.75 [dt, J(H2, H1) = 18, J(H2, H3) = 6 Hz, 1 H, H2], 5.41 [d,
3J(H1, H2) = 18 Hz, 1 H, H1], 2.03 (m, 2 H, H3), 1.57 (m, CH2), 1.25
(m, CH2), 0.80 (m, 3 H, H6) [trans-C4H9CH=CHBF3]–; 5.65 (m, 1 H,
H2), 5.31 [dq 3J(H1, H2) = 13, 3J(H1, BF) = 6 Hz, 1 H, H1], 2.19
(m, 2 H, H3), 1.57 (m, CH2), 1.25 (m, CH2), 0.80 (m, 3 H, H6) [cis-
C4H9CH=CHBF3]–; 3.20 (m, 4CH2), 1.57 (m, 4CH2), 1.37 (m, 4CH2),
Preparation of [Bu4N][CF2=CFBF3]: A solution of [Bu4N][BF4]
(0.99 g, 3.0 mmol) in MeCN (5 mL) was added to a solution of
K[CF2=CFBF3] (575 mg, 3.0 mmol) in MeCN (10 mL). The resulting
suspension was stirred for 1 h. The mother liquor was separated from
K[BF4] by sequential centrifugation and decantation. Finally the sol-
vent was evaporated under reduced pressure. The colorless viscous
product was dried in a vacuum desiccator with Sicapent® and gave a
white solid (1.13 g, 2.27 mmol) (yield 92%). 11B NMR (CD2Cl2): δ =
0.5 [ddq 2J(B, F1) = 25, 3J(B, F2trans) = 7, 1J(B, F) = 41 Hz, BF3].
13C{19F2cis,2trans} NMR (CD3CN): δ = 160.4 (C-2), 136.6 [q (1:1:1:1)
d, 1J(C-1, B) = 100, 1J(C-1, F1) = 220 Hz, C-1] ([CF2=CFBF3]–); 59.2,
24.2, 20.2, 13.5 ([(C4H9)4N]+). 19F NMR (CD2Cl2): δ = –102.4 [d,
2J(F2trans, F2cis) = 91 Hz, 1F, F2trans], –125.1 [dd, 2J(F2cis, F2trans) = 91,
3J(F2cis, F1) = 112 Hz, 1F, F2cis], –144.3 [q (1:1:1:1), 1J(F, B) = 41 Hz,
3
0.93 [t, J(H4, H3) = 7 Hz, 4CH3] [(C4H9)4N]+. 11B NMR (CDCl3): δ
= 2.9 [q, 1J(B, F) = 58 Hz, BF3]. 19F NMR (CDCl3): δ = –135.6
[broadened q (1:1:1:1), 3F, BF3] [cis-C4H9CH=CHBF3]–; –140.9
[broadened q (1:1:1:1), 3F, BF3] [trans-C4H9CH=CHBF3]–.
Preparation of [Bu4N][C4H9CϵCBF3]: The salt (650 mg, 94%) was
obtained as
a colorless viscous oil from [Bu4N]Br (570 mg,
1.77 mmol) and K[C4H9CϵCBF3] (333 mg, 1.77 mmol) in MeCN
(10 mL) as described above. 1H NMR (CDCl3): δ = 2.03 [t, 3J(H3,
H4) = 7 Hz, 2 H, H3], 1.36 (m, 2CH2), 0.78 [t, 3J(H6, H5) = 7 Hz,
3 H, H6] [C4H9CϵCBF3]–; 3.19 (m, 4CH2), 1.56 (m, 4CH2), 1.36 (m,
4CH2), 0.92 [t, 3J(H4, H3) = 7 Hz, 4CH3] [(C4H9)4N]+. 11B NMR
(CDCl3): δ = –1.6 (br. s, Δν1/2 = 126 Hz, BF3). 19F NMR (CDCl3): δ
= –133.9 [broadened q (1:1:1:1), 3F, BF3].
3
3F, BF3], –196.3 [d, J(F1, F2cis) = 112 Hz, 1F, F1] ppm.
Preparation of [Bu4N][CF2=C(CF3)BF3]: The salt (310 mg, 70%)
was obtained from [Bu4N][BF4] (288 mg, 0.87 mmol) and
K[CF2=C(CF3)BF3] (207 mg, 0.87 mmol) in MeCN (2 mL) as de-
scribed above. 13C {19F} NMR (CD2Cl2): δ = 157.7 (F2C=), 126.8
Preparation of [Bu4N][C4H9BF3]: The salt (710 mg, 91%) was pre-
(F3CC=), 84.9 [q (1:1:1:1), 1J(C-1, B) = 80 Hz, C-1] ([CF2=C(CF3) pared as a colorless viscous oil from [Bu4N]Br (680 mg, 2.13 mmol)
BF3]–); 58.9, 23.9, 19.9, 13.0 ([(C4H9)4N]+). 19F NMR (CD2Cl2): δ =
and K[C4H9BF3] (349 mg, 2.13 mmol) in MeCN (10 mL) as described
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Z. Anorg. Allg. Chem. 2012, 565–579